Changes in tumor size during the course of radiotherapy warrant performing adaptive radiotherapy (ART).
Thus, subjective evaluations, including changes in tumor nodules, density, and vascularization, as well as changes in tumor size, are optimal in evaluating therapeutic responses by CT [6].
However, changes in tumor size would also affect the voxel intensity distribution if the relative volume reduction of hypo- and hyper-intense tissue regions was not equal.
This work demonstrated that quantitative MRI biomarkers have the sensitivity to differentiate treatment response in HER2 + tumors prior to changes in tumor size.
To quantify changes in tumor size and tumor-free margins following surgical resection and formalin fixation of oral cavity squamous cell carcinoma.
This method relies on changes in tumor size, which is likely a crude surrogate for alterations in tumor proliferation or cell death, which may occur much sooner than tumor shrinkage.
In the past, we have relied on measuring changes in tumor size, initially from chest X-rays and presently in CT images, following various classifications and recommendations: The World Health Organization (WHO) classification from 1979 [1], followed by Response Evaluation Criteria In Solid Tumors (RECIST) from 2000 [2] updated in 2009 to RECIST 1.1 [3].
The early reductions in tumor cell proliferation preceded changes in tumor size.
Tumor contour was clearly visible on bioluminescent imaging and changes in tumor size, shape, and regions of hypoxia were observed.
For animals treated with mcr84 or GU81, we found that decreases in serum levels of IL-1β and IL-6 were highly correlative with changes in tumor size in the presence of anti-VEGF therapy (Fig. 8A C).
Furthermore, we were able to clearly track tumor growth and development longitudinally over several weeks and were able to observe changes in tumor size in response to chemotherapeutic treatment using this system.
